ClinicalTrials.gov term: Non-alcoholic Fatty Liver Disease
43 trials changed in the last 30 days: 0 stopped, 14 with notable changes, 29 with minor changes only.
Primary and study completion pushed from Jun 30, 2026 to Jul 14, 2027
University of California, DavisNot specified NCT02754037 Registry history of NCT02754037 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Aug 31, 2028 to Feb 28, 2029
Also in this update: Phase changed: Phase 2/3 → Phase 4; Recruitment opened
West China HospitalPhase 4 NCT07718126 Registry history of NCT07718126 on ClinicalTrials.gov (opens the registry)
Primary completion pushed from Mar 2026 to Mar 2028
Also in this update: Trial status changed: Unknown → Recruiting; Study completion pushed from Jun 2026 to Sep 2028
Marialena MouzakiPhase 2 NCT06133101 Registry history of NCT06133101 on ClinicalTrials.gov (opens the registry)
Primary endpoint(s) modified
Also in this update: Trial status changed: Not Yet Recruiting → Active, Not Recruiting
Novo Nordisk A/SNot specified NCT07781371 Registry history of NCT07781371 on ClinicalTrials.gov (opens the registry)
Primary endpoint(s) modified
Linkoeping UniversityNot specified NCT07312136 Registry history of NCT07312136 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Trial sites expanded: 0 → 16 locations; Start date changed from estimate of Sep 2026 to Oct 7, 2026
Madrigal Pharmaceuticals, Inc.Phase 4 NCT07848191 Registry history of NCT07848191 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Trial sites expanded: 0 → 5 locations
Madrigal Pharmaceuticals, Inc.Phase 1 NCT07830758 Registry history of NCT07830758 on ClinicalTrials.gov (opens the registry)
Recruitment opened
Also in this update: Enrollment increased: 400 → 886 participants
Haisco Pharmaceutical Group Co., Ltd.Phase 3 NCT07581951 Registry history of NCT07581951 on ClinicalTrials.gov (opens the registry)
Start date pushed from Sep 4, 2024 to Oct 4, 2024
Also in this update: Trial sites expanded: 331 → 345 locations
Akero Therapeutics, IncPhase 3 NCT06528314 Registry history of NCT06528314 on ClinicalTrials.gov (opens the registry)
Reclassified as terminated (was completed)
And 3 more changes in the last 30 days
University of MinnesotaNot applicable NCT03587831 Registry history of NCT03587831 on ClinicalTrials.gov (opens the registry)
Results posted: Oct 14, 2026
Adrian VellaPhase 1/2 NCT05500586 Registry history of NCT05500586 on ClinicalTrials.gov (opens the registry)
Enrollment increased: 62 → 182 participants
Also in this update: Enrollment closed, study ongoing; Study completion pushed from Jun 30, 2026 to Dec 30, 2026
Seoul National University HospitalNot applicable NCT07192159 Registry history of NCT07192159 on ClinicalTrials.gov (opens the registry)
Results posted: Sep 30, 2026
Columbia UniversityPhase 1 NCT05729282 Registry history of NCT05729282 on ClinicalTrials.gov (opens the registry)
Primary completion date changed from estimate of Mar 31, 2025 to Sep 30, 2025
Also in this update: Trial completed
The Third People's Hospital of ChengduNot specified NCT06720766 Registry history of NCT06720766 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Primary completion date changed from estimate of Oct 30, 2026 to Sep 22, 2026
Corcept TherapeuticsPhase 1 NCT07553663 Registry history of NCT07553663 on ClinicalTrials.gov (opens the registry)
Enrollment closed, study ongoing
Also in this update: Final enrollment: 29 participants (planned 60)
Novo Nordisk A/SPhase 1 NCT07214870 Registry history of NCT07214870 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Primary completion date changed from estimate of Sep 2026 to Feb 13, 2026
Corcept TherapeuticsPhase 2 NCT06108219 Registry history of NCT06108219 on ClinicalTrials.gov (opens the registry)
Trial completed
Merck Sharp & Dohme LLCPhase 2 NCT06465186 Registry history of NCT06465186 on ClinicalTrials.gov (opens the registry)
Trial completed
Corcept TherapeuticsPhase 1 NCT06947304 Registry history of NCT06947304 on ClinicalTrials.gov (opens the registry)
Trial status changed: Enrolling by Invitation → Active, Not Recruiting
University Health Network, TorontoPhase 4 NCT05195944 Registry history of NCT05195944 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Study completion date changed from estimate of May 1, 2026 to Jan 22, 2026
TCM Biotech International Corp.Not applicable NCT05930093 Registry history of NCT05930093 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Study completion date changed from estimate of Jul 30, 2026 to Jun 3, 2026; Final enrollment: 43 participants (planned 52)
BAR Pharmaceuticals s.r.l.Phase 1 NCT06705998 Registry history of NCT06705998 on ClinicalTrials.gov (opens the registry)
Trial status changed: Not Yet Recruiting → Active, Not Recruiting
Also in this update: Study completion pushed from Feb 28, 2027 to Dec 30, 2027; Primary completion moved earlier from Dec 30, 2026 to Oct 7, 2026
Seoul National University HospitalNot specified NCT07530419 Registry history of NCT07530419 on ClinicalTrials.gov (opens the registry)
Trial completed
Also in this update: Primary completion date changed from estimate of Sep 2026 to Dec 7, 2025
Washington University School of MedicineNot applicable NCT01104220 Registry history of NCT01104220 on ClinicalTrials.gov (opens the registry)
Completed without a posted recruiting period
Cairo UniversityNot applicable NCT07200934 Registry history of NCT07200934 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 11 → 25 locations
Boehringer IngelheimPhase 3 NCT07850063 Registry history of NCT07850063 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 356 → 359 locations
Akero Therapeutics, IncPhase 3 NCT06215716 Registry history of NCT06215716 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 4 → 7 locations
Novartis PharmaceuticalsNot specified NCT07683065 Registry history of NCT07683065 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 64 → 68 locations
EccogenePhase 2 NCT07288138 Registry history of NCT07288138 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 367 → 370 locations
89bio, Inc.Phase 3 NCT06318169 Registry history of NCT06318169 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 326 → 330 locations
89bio, Inc.Phase 3 NCT06419374 Registry history of NCT06419374 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 7 → 15 locations
GlaxoSmithKlinePhase 3 NCT07701993 Registry history of NCT07701993 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 12 → 20 locations
GlaxoSmithKlinePhase 3 NCT07704892 Registry history of NCT07704892 on ClinicalTrials.gov (opens the registry)
Trial sites expanded: 6 → 9 locations
Regeneron PharmaceuticalsPhase 2 NCT07527910 Registry history of NCT07527910 on ClinicalTrials.gov (opens the registry)
Final enrollment: 56 participants (planned 50)
Hoffmann-La RochePhase 1 NCT06903065 Registry history of NCT06903065 on ClinicalTrials.gov (opens the registry)
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Active, Not Recruiting
Yokohama City UniversityPhase 2 NCT06623539 Registry history of NCT06623539 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Not Yet Recruiting
Stefania BasiliNot specified NCT06623084 Registry history of NCT06623084 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
Jinling Hospital, ChinaNot applicable NCT06619808 Registry history of NCT06619808 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Not Yet Recruiting
Assiut UniversityNot specified NCT06601361 Registry history of NCT06601361 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
Cairo UniversityNot applicable NCT06596109 Registry history of NCT06596109 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
Cairo UniversityNot applicable NCT06591169 Registry history of NCT06591169 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Oct 2023); last known: Not Yet Recruiting
Qianfoshan HospitalNot specified NCT06097338 Registry history of NCT06097338 on ClinicalTrials.gov (opens the registry)
Changed
Registry verification sweep
Changed
Registry marked status Unknown (sponsor has not verified the record since Oct 2023); last known: Recruiting
University of TriesteNot specified NCT06098417 Registry history of NCT06098417 on ClinicalTrials.gov (opens the registry)
Changed
| First posted | Trial | Sponsor | Phase |
|---|---|---|---|
| 2026-10-19 | NCT07881796 Effect of Dapagliflozin on Metabolic Parameters in Patients With Non-Alcoholic Fatty… | Shalamar Hospital new | |
| 2026-10-16 | NCT07878091 A Phase 2a Study of Kylo-0603 Capsule in Participants With Metabolic Dysfunction… | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. new | Phase 2 |
| 2026-10-16 | NCT07877272 Endohepatology-Based Reclassification of Treatment Indication in High-Risk MASLD | University Hospital Muenster new | |
| 2026-10-08 | NCT07865936 Cardiovascular Risk Assessment and Coronary Calcium Score in Thai MASLD Patients | Watcharasak Chotiyaputta new | |
| 2026-10-06 | NCT07861191 RESET-INSPIRE Study: Insulin Sensitivity & Population Intervention With Real-time… | National University Health System, Singapore new | |
| 2026-10-06 | NCT07860814 Ultrasound Biomarkers for Assessing Eligibility and Response to Resmetirom Therapy | Radnet Management, Inc. new | |
| 2026-09-22 | NCT07833514 Misocholic Tablets for Non-Viral Elevated Liver Enzymes | Hanoi Medical University new | Phase 3 |
| 2026-09-16 | NCT07821749 A Prospective Study of Cold Exposure in Patients With MASH | Renmin Hospital of Wuhan University new | |
| 2026-09-11 | NCT07816211 External Transportability Validation, Implementation Readiness, and Outcome Association… | Anhui Provincial Hospital new | |
| 2026-09-03 | NCT07801313 Phase 1 Clinical Study of MWN105 Injection in Healthy Chinese Volunteers | Shanghai Minwei Biotechnology Co., Ltd new | Phase 1 |
| Early Phase 1 | 7 | |
| Phase 1 | 24 | |
| Phase 1/2 | 9 | |
| Phase 2 | 68 | |
| Phase 3 | 29 | |
| Phase 4 | 22 |
Assiut University (19) · Beijing Friendship Hospital (9) · Madrigal Pharmaceuticals, Inc. (8) · GlaxoSmithKline (7) · Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis (6) · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico (6) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (6) · Regeneron Pharmaceuticals (6) · University of California, San Diego (6) · Cairo University (5)